Coldstream Capital Management Inc. boosted its holdings in Lam Research Co. (NASDAQ:LRCX – Free Report) by 725.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,404 shares of the semiconductor company’s stock after buying an additional 69,782 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Lam Research were worth $5,735,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parisi Gray Wealth Management grew its holdings in shares of Lam Research by 652.9% during the 4th quarter. Parisi Gray Wealth Management now owns 8,350 shares of the semiconductor company’s stock valued at $603,000 after purchasing an additional 7,241 shares during the last quarter. Burns J W & Co. Inc. NY bought a new stake in shares of Lam Research during the fourth quarter worth $815,000. Centerpoint Advisors LLC increased its holdings in shares of Lam Research by 900.0% during the fourth quarter. Centerpoint Advisors LLC now owns 1,000 shares of the semiconductor company’s stock worth $72,000 after buying an additional 900 shares in the last quarter. Transform Wealth LLC bought a new position in shares of Lam Research in the 4th quarter valued at $17,269,000. Finally, E. Ohman J or Asset Management AB acquired a new stake in shares of Lam Research during the 4th quarter valued at $4,258,000. Institutional investors own 84.61% of the company’s stock.
Insiders Place Their Bets
In other news, SVP Seshasayee Varadarajan sold 110,080 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $90.00, for a total value of $9,907,200.00. Following the completion of the sale, the senior vice president now owns 179,084 shares in the company, valued at $16,117,560. This represents a 38.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.29% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on LRCX
Lam Research Stock Performance
Shares of LRCX opened at $71.42 on Friday. Lam Research Co. has a one year low of $56.32 and a one year high of $113.00. The company has a market cap of $91.68 billion, a PE ratio of 21.70, a P/E/G ratio of 1.47 and a beta of 1.52. The stock has a 50-day moving average of $73.15 and a 200-day moving average of $75.48. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.54 and a quick ratio of 1.73.
Lam Research (NASDAQ:LRCX – Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The semiconductor company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Lam Research had a return on equity of 51.86% and a net margin of 26.49%. The firm had revenue of $4.72 billion during the quarter, compared to analysts’ expectations of $4.64 billion. On average, equities research analysts predict that Lam Research Co. will post 3.71 EPS for the current fiscal year.
Lam Research Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, April 9th. Shareholders of record on Wednesday, March 5th were paid a dividend of $0.23 per share. The ex-dividend date was Wednesday, March 5th. This represents a $0.92 dividend on an annualized basis and a yield of 1.29%. Lam Research’s dividend payout ratio (DPR) is currently 27.96%.
Lam Research Company Profile
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.
Recommended Stories
- Five stocks we like better than Lam Research
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Short Sellers Gave Up on These 3 Names Recently
- Compound Interest and Why It Matters When Investing
- 3 Boring Stocks Outperforming the Market This Year
- What Are Dividend Challengers?
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Lam Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lam Research and related companies with MarketBeat.com's FREE daily email newsletter.